3DBiopsy, Inc.— founded by noted experts Drs. Stone, Crawford and Lucia—has developed a Biopsy System* that uses
three-dimensional (3D) imaging to map the prostate gland to aid in identifying the location of clinically significant cancers. It was created in response to the frustration that physicians, patients and the healthcare system experience with the current biopsy
method—Transrectal Ultrasound (TRUS).
The 3DBiopsy System includes a patented Biopsy Needle, patented Biopsy Actuator device, patent-pending Integrated Pathology System and 3D Mapping Software.
The company hopes that this 4-part advance in the diagnosis and treatment of prostate cancer will result in a paradigm shift in the management of this disease—
and ultimately, other cancers.
*Investigational device. Not available for sale in the United States
& Investment information
is available on request.
Brad J. Buscher
Chairman of the Board
Nelson N. Stone, MD
President, Chief Executive Officer
James R. Rosa
Vice President, Regulatory
and Quality Assurance
Todd J. Anderson
Chief Financial Officer
E. David Crawford, MD
Chief Medical Advisor
We welcome inquiries from Investors.
call direct: 1-800-290-6186
© 2016 3DBiopsy, Inc.
Design: Boscia Trott